TY - JOUR
T1 - Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction
AU - Cittadini, Antonio
AU - Saldamarco, Lavinia
AU - Marra, Alberto Maria
AU - Arcopinto, Michele
AU - Carlomagno, Guido
AU - Imbriaco, Massimo
AU - Del Forno, Domenico
AU - Vigorito, Carlo
AU - Merola, Bartolomeo
AU - Oliviero, Ugo
AU - Fazio, Serafino
AU - Saccà, Luigi
PY - 2009/9
Y1 - 2009/9
N2 - Context: A reduced activity of the GH/IGF-I axis in chronic heart failure (CHF) has been described by several independent groups and is associated with poor clinical status and outcome. Objective: The aim of the current study was to investigate the prevalence of GH deficiency in a patient population with CHF and evaluate the cardiovascular effects of GH replacement therapy. Design and Setting: The randomized, single-blind, controlled trial was conducted at the Federico II University. Participants: One hundred fifty-eight patients with CHF, New York Heart Association class II-IV, underwent a GH stimulation test. Sixty-three patients satisfied the criteria for GH deficiency, and 56 of them were enrolled in the trial. Intervention: The treated group (n = 28) received GH at a replacement dose of 0.012 mg/kg every second day (∼2.5 IU). Main Outcomes Measures: Changes in physical performance and various cardiovascular indexes were measured. Results: GH replacement therapy improved quality of life score (from 46 ± 5 to 38 ± 4; P <0.01), increased peak oxygen uptake and exercise duration (from 12.9±.9 to 14.5±1 ml/kg · min and from 520 ± 36 to 586 ± 43 sec, respectively; P <0.01), and flow-mediated vasodilation (from 8.8 ± 1.3 to 12.7±1.2%;P
AB - Context: A reduced activity of the GH/IGF-I axis in chronic heart failure (CHF) has been described by several independent groups and is associated with poor clinical status and outcome. Objective: The aim of the current study was to investigate the prevalence of GH deficiency in a patient population with CHF and evaluate the cardiovascular effects of GH replacement therapy. Design and Setting: The randomized, single-blind, controlled trial was conducted at the Federico II University. Participants: One hundred fifty-eight patients with CHF, New York Heart Association class II-IV, underwent a GH stimulation test. Sixty-three patients satisfied the criteria for GH deficiency, and 56 of them were enrolled in the trial. Intervention: The treated group (n = 28) received GH at a replacement dose of 0.012 mg/kg every second day (∼2.5 IU). Main Outcomes Measures: Changes in physical performance and various cardiovascular indexes were measured. Results: GH replacement therapy improved quality of life score (from 46 ± 5 to 38 ± 4; P <0.01), increased peak oxygen uptake and exercise duration (from 12.9±.9 to 14.5±1 ml/kg · min and from 520 ± 36 to 586 ± 43 sec, respectively; P <0.01), and flow-mediated vasodilation (from 8.8 ± 1.3 to 12.7±1.2%;P
UR - http://www.scopus.com/inward/record.url?scp=69949126965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69949126965&partnerID=8YFLogxK
U2 - 10.1210/jc.2009-0533
DO - 10.1210/jc.2009-0533
M3 - Article
C2 - 19584187
AN - SCOPUS:69949126965
VL - 94
SP - 3329
EP - 3336
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 9
ER -